Is the Covid vaccine effective and safe?
| dc.contributor.author | Toure, Sogona | |
| dc.contributor.author | Rubinstein, Sofia | |
| dc.contributor.author | Short, Grace | |
| dc.contributor.author | Rubio, Priscilla A | |
| dc.contributor.author | Li, Yunxiang | |
| dc.date.accessioned | 2021-03-19T23:18:45Z | |
| dc.date.available | 2021-03-19T23:18:45Z | |
| dc.date.issued | 2021 | |
| dc.description | Creative Arts and Research Symposium | |
| dc.description | Creative Arts and Research Symposium | en_US |
| dc.description.abstract | COVID-19 is a new disease, caused by a novel (or new) coronavirus that has not previously been seen in humans. It is thought to spread mainly through close contact from person to person, including between people who are physically near each other (within about 6 feet). We will investigate its effectiveness and safety of the vaccine. Randomly assigned persons 16 years of age or older in a 1:1 ratio received two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). After the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). It was concluded that A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccine. | |
| dc.description.department | Chemistry and Biochemistry | |
| dc.identifier.uri | https://hdl.handle.net/11274/12897 | |
| dc.language.iso | en_US | en_US |
| dc.title | Is the Covid vaccine effective and safe? | en_US |
| dc.type | Poster | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.68 KB
- Format:
- Item-specific license agreed upon to submission
- Description: